On the dual nature of monoamine oxidase.
D000818:Animals; D000928:Antidepressive Agents; D001665:Binding Sites; D001921:Brain / Q000201:enzymology; D002395:Catecholamines / Q000378:metabolism; D003010:Clorgyline / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007980:Levodopa / Q000378:metabolism; D008928:Mitochondria / Q000201:enzymology; D008930:Mitochondria, Liver / Q000201:enzymology; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000378:metabolism / Q000627:therapeutic use; D009541:Nictitating Membrane / Q000187:drug effects; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy; D010627:Phenethylamines / Q000378:metabolism / Q000494:pharmacology; D011437:Propylamines / Q000378:metabolism; D011485:Protein Binding; D012701:Serotonin / Q000378:metabolism; D013329:Structure-Activity Relationship; D014439:Tyramine / Q000378:metabolism
D000928:Antidepressive Agents; D002395:Catecholamines; D008996:Monoamine Oxidase Inhibitors; D010627:Phenethylamines; D011437:Propylamines; D012701:Serotonin; D007980:Levodopa; D008995:Monoamine Oxidase; D003010:Clorgyline; D009638:Norepinephrine; D014439:Tyramine